中國醫療集團(08225.HK)：擬與加拿大公司開展國際生物等效性試驗和國際註冊
格隆匯3月5日丨中國醫療集團(08225.HK)公佈，集團關聯製造企業於2020年2月25日獲得抗病毒產品邁可欣(利托那韋口服液)國藥準字 H20051019 生產註冊批准後，收到多國採購需求，集團擬與一家加拿大公司開展國際生物等效性試驗和國際註冊。
人類和病毒疫情的戰鬥將是長久。由於新冠病毒在中國境外已經涉及73個國家，據查目前全球生產利托那韋製劑的企業只有兩家。利托那韋(Ritonavir)被中國科學院和美國等研究機構報導對新型冠狀病毒(2019-nCoV)有抑制作用。洛匹那韋/利托那韋連續七次被列入《 國家衞健委批准的抗擊冠狀病毒臨牀方案 》。
英國"自然"雜誌(Nature Reviews Drug Discovery)於2020年2月10 日發表的《Therapeutic options for the 2019 novel coronavirus (2019-nCoV)》建議現有的抗愛滋病病毒及丙肝病毒藥物有可能對新型冠狀病毒有抑制作用。中國境內由南昌市第九醫院陳宏義主任團隊發起的利托那韋聯合口服達諾瑞韋鈉片治療新型冠狀病毒肺炎臨牀研究也已經取得了積極成果。
集團正與高濟醫療、海王星辰、微醫集團、妙手醫療等建立研究數字型專區藥診，聚焦危機心理專區，拜敏抗敏專區，戒煙長命專區。致力於疫情後時代疫情心理與過敏治療。危機心理疾病致殘死亡將超越新冠病毒肺炎身。吸煙患者死亡率也遠高於非吸煙患者。
集團在疫情和醫療新時代推出兩個模式，1."研究型治療 RWS-Therapy 模式"即通過真實世界臨牀研究開展對 COVID19 臨牀和大資料研究，在研究中指導用藥治療，在治療中獲得醫療大資料指導研究。2.數位臨牀研究型推廣平台 D-CRCO模式(Digital 數位化 Clinical 臨牀 Research 研究 commercializaton 商業化organization 組織)，用大資料臨牀研究精準賦能產品商業化。這兩個模式將數位化重新定義研究型治療和研究型推廣替代傳統治療和商業化方式。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
